Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-10-19, Stock:NVS, The news for the past five days is as follows:
2018-10-12: NEWS1: AbbVie Permits US Sale of Sandoz's Humira Biosimilar.NEWS2: 3 Large-Cap Pharma Stocks Performing Better Than Industry.NEWS3: 3 Large-Cap Pharma Stocks Performing Better Than Industry.NEWS4: Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal.NEWS5: Pharma Stock Roundup: ABBV, NVS' Humira Biosimilar Agreement, BMY's New Cancer Deal.NEWS6: AbbVie Settles With Novartis to Delay Humira Biosimilar in US.NEWS7: AbbVie Settles With Novartis to Delay Humira Biosimilar in US.NEWS8: Pharma Stock Roundup: ABBV, NVS&apos; Humira Biosimilar Agreement, BMY&apos;s New Cancer Deal.NEWS9: AbbVie Settles With Novartis to Delay Humira Biosimilar in US.NEWS10: Abbvie settles Humira patent disputes with Novartis unit.NEWS11: Abbvie settles Humira patent disputes with Novartis unit.
2018-10-15: NEWS1: Trump administration: Drug makers should disclose prices in TV ads.NEWS2: Novartis’ Estimates and Recommendations on October 12.NEWS3: Novartis in Q3 2018: Analysts Expect Revenue Growth.NEWS4: Novartis: What to Expect from Q3 Earnings on October 18.NEWS5: An Update on Bausch + Lomb/International in October.
2018-10-16: NEWS1: Alnylam to Pursue Full Approval & Rolling NDA for Givosiran.NEWS2: Alnylam to Pursue Full Approval & Rolling NDA for Givosiran.NEWS3: Tesla Jumps After Judge Makes SEC Settlement Official: LIVE MARKETS BLOG.NEWS4: Benchmark Out Bullish On 'Well-Positioned' Tilray Ahead of Canada's Cannabis Legalization.NEWS5: Tilray Jumps After $200 Price Target and 'Buy' Rating: LIVE MARKETS BLOG.NEWS6: Tilray Jumps After $200 Price Target and Bullish Rating at Benchmark.NEWS7: Roche Announces Positive Data on Breast Cancer Drug Kadcyla.NEWS8: Amgen, Novartis kick off fight for AbbVie blockbuster drug in EU.NEWS9: Tilray&apos;s stock surges after Benchmark starts coverage with bullish rating, $200 target.NEWS10: Novartis To Present Five-year Data From Phase III Studies For Cosentyx.NEWS11: Novartis To Present Five-year Data From Phase III Studies For Cosentyx.
2018-10-17: NEWS1: Health Care Sector Update for 10/17/2018: TEVA,ESRX,AMGN,NVW,LLY,VTVT,KDMN,FMS.NEWS2: Health Care Sector Update for 10/17/2018: TEVA,ESRX,AMGN,NVW,LLY,VTVT,KDMN,FMS.NEWS3: Pre-Market Earnings Report for October 18, 2018 :  PM, DHR, BK, BBT, TRV, NVS, ERIC, BX, PPG, KEY, NUE, TXT.NEWS4: Pre-Market Earnings Report for October 18, 2018 :  PM, DHR, BK, BBT, TRV, NVS, ERIC, BX, PPG, KEY, NUE, TXT.NEWS5: Novartis Q3 Earnings Preview.
2018-10-18: NEWS1: [$$] Novartis to Buy Cancer-Drug Maker Endocyte for $2.1 Billion.NEWS2: Close Update: Stocks Slump Thursday Amid Interest Rate, Economic Growth Concerns.NEWS3: Close Update: Stocks Slump Thursday Amid Interest Rate, Economic Growth Concerns.NEWS4: PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT.NEWS5: PTI Jumps Over 400% On CF Data, GRTS, YMAB March Ahead, NVS Acquires ECYT.NEWS6: Health Care Sector Update for 10/18/2018: ECYT,EIGR,NVS,PTI,ACRS.NEWS7: Health Care Sector Update for 10/18/2018: ECYT,EIGR,NVS,PTI,ACRS.NEWS8: Endocyte&apos;s $2.1 Billion Deal Rewards Investors Who Stuck It Out.NEWS9: Novartis Missed Revenue Estimates in Q3 2018.NEWS10: Novartis to Buy Biopharmaceutical Company Endocyte for $2.1 Billion.NEWS11: Mid-Day Update: U.S. Stocks Skid as Mnuchin Pulls Out of Saudi Conference, Italian Rout Triggered by Draghi.NEWS12: Mid-Day Update: U.S. Stocks Skid as Mnuchin Pulls Out of Saudi Conference, Italian Rout Triggered by Draghi.NEWS13: FDA snubs Novartis bid to repurpose inflammation drug for heart attacks.NEWS14: Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates.NEWS15: Mid-Morning Market Update: Markets Open Lower; Philip Morris Profit Beats Estimates.NEWS16: Why Endocyte, Inc. Stock Is Soaring Today.NEWS17: Why Endocyte, Inc. Stock Is Soaring Today.NEWS18: Novartis buying cancer drug maker Endocyte for $2.1B.NEWS19: Novartis Reports Positive Long-Term Data From Cosentyx Trials.NEWS20: Novartis Gets Key Therapy -- For Almost 200 Times Its Last Price.NEWS21: Why Endocyte, Inc. Stock Is Soaring Today.NEWS22: Health Care Sector Update for 10/18/2018: ECYT, NVS, DHR, PTI, JNJ, PFE, ABT, MRK, AMGN.NEWS23: Health Care Sector Update for 10/18/2018: ECYT, NVS, DHR, PTI, JNJ, PFE, ABT, MRK, AMGN.NEWS24: Wall Street Tumbles Ahead of Opening Bell After Hawkish Fed Minutes.NEWS25: Wall Street Tumbles Ahead of Opening Bell After Hawkish Fed Minutes.NEWS26: Novartis Secures Prostate Cancer Treatment With Endocyte Deal.NEWS27: Novartis To Buy Endocyte In $2.1B Deal.NEWS28: Pre-Market Most Active for Oct 18, 2018 :  ECYT, PTI, AZN, ERIC, NOK, ACHC, QQQ, SQQQ, HSBC, NIO, LYG, NVS.NEWS29: Pre-Market Most Active for Oct 18, 2018 :  ECYT, PTI, AZN, ERIC, NOK, ACHC, QQQ, SQQQ, HSBC, NIO, LYG, NVS.NEWS30: US Futures Tumble After Hawkish Fed Minutes.NEWS31: US Futures Tumble After Hawkish Fed Minutes.NEWS32: The Daily Biotech Pulse: Novartis Buys Endocyte, Proteostasis Positive Cystic Fibrosis Trial, 2 IPOs.NEWS33: Earnings Reaction History: Novartis AG, 66.7% Follow-Through Indicator, 2.6% Sensitive.NEWS34: Earnings Reaction History: Novartis AG, 66.7% Follow-Through Indicator, 2.6% Sensitive.NEWS35: Endocyte stock pops 50% on $2.1 bln Novartis acquisition.NEWS36: [$$] European Equities Market Talk Roundup.NEWS37: Novartis pushes deeper into nuclear medicine with $2.1 billion deal.NEWS38: Novartis: 3Q Earnings Snapshot.NEWS39: Novartis pushes deeper into nuclear medicine with $2.1 bln deal.NEWS40: [$$] European Corporate News Roundup.NEWS41: Endocyte Enters Into Agreement to be Acquired by Novartis for $24/Share.NEWS42: Novartis to buy cancer drugmaker Endocyte for $2.1 billion in cash.NEWS43: Novartis to buy cancer drugmaker Endocyte for $2.1 bln in cash.NEWS44: Novartis Q3 Profit Weak, Lifts FY18 Sales View, To Buy Endocyte; Stock Up.NEWS45: Novartis Q3 Profit Weak, Lifts FY18 Sales View, To Buy Endocyte; Stock Up.NEWS46: Novartis raises 2018 sales outlook as Entresto, Cosentyx accelerate.NEWS47: Shares of cancer drugmaker Endocyte surge 50% on Novartis&apos; $2.1 billion acquisition deal.NEWS48: Shares of cancer drugmaker Endocyte surge 50% on Novartis' $2.1 billion acquisition deal.NEWS49: Novartis to buy Endocyte for $2.1 billion in cash.NEWS50: Novartis CEO: No fundamental changes to operations from B....NEWS51: Novartis Q3 Profit Down; But Lifts 2018 Net Sales View.NEWS52: Novartis Q3 Profit Down; But Lifts 2018 Net Sales View.NEWS53: Novartis To Acquire Endocyte - Quick Facts.NEWS54: Novartis To Acquire Endocyte - Quick Facts.

Answer: Rise